Share on facebook Share on Twitter Share on Google Plus Share This
Back to Results

CX-8998 for Absence Seizures


Title A Phase 2a, Safety, Tolerability, Pharmacokinetics and Quantitative EEG Study of CX-8998 in Adolescents and Young Adults with Generalized Epileptic Syndromes with Absence Seizures
Therapeutic Area Seizures
Principal Investigator Joel Oster, MD
Min Age 18 Years
Max Age 45 Years
Gender Any
Contact Lindsey Soll
617-636-7620
More Information https://www.clinicaltrials.gov/ct2/show/NCT03406702

Overview

This is a 9-week, phase 2a, multicenter, double-blind, placebo-controlled, parallel-group study in young adults with generalized epileptic syndromes with absence seizures. The primary objective of the study is to determine the safety and tolerability of the study drug, CX-8998.

Study Details

Inclusion Criteria

  • Diagnosed with an epileptic syndrome with absence seizures.
  • Absence seizures persisting despite trials with at least 2 standard anti-epileptic treatment.
  • On a stable dose or one or more anti-epileptic medications for at least 30 days or not on any therapy.

Exclusion Criteria

  • History of focal epilepsy for epileptiform patterns.
  • History of surgical intervention for treatment of epilepsy.
  • Inadequately treated psychotic or mood disorder or severe intellectual or developmental disorder.

Study Requirements

Number of research visits: 3

Number of nurse home visits: 3

Length of participation: 9 weeks

Number of blood collections: 3